PT Kalbe Farma Tbk. (PTKFF)

USD 0.08

(0.0%)

EBITDA Summary of PT Kalbe Farma Tbk.

  • PT Kalbe Farma Tbk.'s latest annual EBITDA in 2023 was 288.13 Million USD , down -10.74% from previous year.
  • PT Kalbe Farma Tbk.'s latest quarterly EBITDA in 2024 Q3 was 61.89 Million USD , down -22.49% from previous quarter.
  • PT Kalbe Farma Tbk. reported an annual EBITDA of 335.74 Million USD in 2022, down -3.31% from previous year.
  • PT Kalbe Farma Tbk. reported an annual EBITDA of 325.68 Million USD in 2021, up 10.48% from previous year.
  • PT Kalbe Farma Tbk. reported a quarterly EBITDA of 61.89 Million USD for 2024 Q3, down -22.49% from previous quarter.
  • PT Kalbe Farma Tbk. reported a quarterly EBITDA of 88.38 Million USD for 2024 Q1, up 19.96% from previous quarter.

Annual EBITDA Chart of PT Kalbe Farma Tbk. (2023 - 2015)

Historical Annual EBITDA of PT Kalbe Farma Tbk. (2023 - 2015)

Year EBITDA EBITDA Growth
2023 288.13 Million USD -10.74%
2022 335.74 Million USD -3.31%
2021 325.68 Million USD 10.48%
2020 309.91 Million USD 7.87%
2019 273.3 Million USD 8.32%
2018 264.18 Million USD -4.82%
2017 274.63 Million USD 4.52%
2016 264.24 Million USD 18.5%
2015 214.03 Million USD 0.0%

Peer EBITDA Comparison of PT Kalbe Farma Tbk.

Name EBITDA EBITDA Difference
AstraZeneca PLC 13.28 Billion USD 97.832%
Bristol-Myers Squibb Company PFD CONV 2 19.41 Billion USD 98.516%
CSPC Pharmaceutical Group Limited 1.14 Billion USD 74.903%
Clarus Therapeutics Holdings, Inc. -39.7 Million USD 825.686%
Novartis AG 19.51 Billion USD 98.524%